These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10772377)

  • 1. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis.
    Lawrence M; Guay DR; Benson SR; Anderson MJ
    Pharmacotherapy; 2000 Apr; 20(4):470-5. PubMed ID: 10772377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin.
    Rovner ES; Wein AJ
    BJU Int; 2000 Oct; 86 Suppl 2():44-53; discussion 53-4. PubMed ID: 11501617
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective.
    O'Brien BJ; Goeree R; Bernard L; Rosner A; Williamson T
    Clin Ther; 2001 Dec; 23(12):2038-49. PubMed ID: 11813937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
    Hughes DA; Dubois D
    Pharmacoeconomics; 2004; 22(16):1047-59. PubMed ID: 15524493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
    Ethans KD; Nance PW; Bard RJ; Casey AR; Schryvers OI
    J Spinal Cord Med; 2004; 27(3):214-8. PubMed ID: 15478523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
    Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine: a clinical review.
    Crandall C
    J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
    Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
    Jumadilova Z; Varadharajan S; Girase P; Ollendorf DA
    Am J Health Syst Pharm; 2006 Dec; 63(23):2357-64. PubMed ID: 17106009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative adherence to oxybutynin or tolterodine among older patients.
    Gomes T; Juurlink DN; Mamdani MM
    Eur J Clin Pharmacol; 2012 Jan; 68(1):97-9. PubMed ID: 21710237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.
    Harvey MA; Baker K; Wells GA
    Am J Obstet Gynecol; 2001 Jul; 185(1):56-61. PubMed ID: 11483904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
    Abrams P; Freeman R; Anderström C; Mattiasson A
    Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
    Perfetto EM; Subedi P; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which anticholinergic drug for overactive bladder symptoms in adults.
    Hay-Smith J; Herbison P; Ellis G; Morris A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder.
    Drutz HP; Appell RA; Gleason D; Klimberg I; Radomski S
    Int Urogynecol J Pelvic Floor Dysfunct; 1999; 10(5):283-9. PubMed ID: 10543335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The newer antimuscarinic drugs: bladder control with less dry mouth.
    Appell RA
    Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.
    Homma Y; Kawabe K
    World J Urol; 2004 Oct; 22(4):251-6. PubMed ID: 15455256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder.
    Getsios D; Caro JJ; Ishak KJ; El-Hadi W; Payne K
    Clin Ther; 2004 Mar; 26(3):431-8. PubMed ID: 15110136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.